Aimaretti Gianluca, Ghigo Ezio
Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Turin, Turin, Italy.
ScientificWorldJournal. 2005 Sep 15;5:777-81. doi: 10.1100/tsw.2005.100.
Results of recent and ongoing studies have made it clear that brain injuries like traumatic brain injury (TBI) pose substantial risk to pituitary function, perhaps even greater risk than previously believed. Patients with TBI should be screened both prospectively and retrospectively for isolated, multiple and even total pituitary deficits. It is well known that, patients with "classical" hypopituitarism (due to primary hypothalamic-pituitary pathologies) do benefit from hormonal replacement therapy. It has been suggested that patients with TBI-induced hypopituitarism may benefit with appropriate hormonal replacement receiving replacement therapy such as anti-diuretic hormone (ADH), glucocorticoid and thyroid hormones when needed. Gonadal and recombinant human growth hormone (rhGH) replacement therapy should also be introduced if there are deficiencies demonstrated and even reconfirmed in a second step. The signs and symptoms of post-TBI hypopituitarism may be masked by what has been assumed to be merely the post-traumatic syndrome. By increasing awareness among physicians of the risks of brain injuries-induced endocrinopathies and the need for appropriate endocrinological testing, it may be possible to improve the quality of life and enhance the rehabilitation prospects for these patients. In most instances, these patients are first seen and treated by trauma surgeons and neurosurgeons, and subsequently by rehabilitation physicians; they must be knowledgeable about the risks of hypopituitarism so that they can determine which patients are candidates for screening for hypopituitarism. In addition, endocrinologists and internists must be educated about TBI-induced hypopituitarism and encouraged to actively share their expertise with other physicians.
近期及正在进行的研究结果已明确表明,诸如创伤性脑损伤(TBI)之类的脑损伤会对垂体功能构成重大风险,其风险可能甚至比之前认为的更大。TBI患者应进行前瞻性和回顾性筛查,以确定是否存在孤立性、多发性甚至全垂体功能减退。众所周知,患有“典型”垂体功能减退(由于原发性下丘脑 - 垂体病变)的患者确实能从激素替代疗法中获益。有人提出,TBI所致垂体功能减退的患者可能会从适当的激素替代疗法中获益,必要时接受抗利尿激素(ADH)、糖皮质激素和甲状腺激素等替代治疗。如果在第二步检查中证实并再次确认存在性腺功能减退和重组人生长激素(rhGH)缺乏,也应进行相应的替代治疗。TBI后垂体功能减退的体征和症状可能会被认为仅仅是创伤后综合征所掩盖。通过提高医生对脑损伤所致内分泌疾病风险以及进行适当内分泌检查必要性的认识,有可能改善这些患者的生活质量并提高其康复前景。在大多数情况下,这些患者首先由创伤外科医生和神经外科医生诊治,随后由康复医生治疗;他们必须了解垂体功能减退的风险,以便确定哪些患者是垂体功能减退筛查的对象。此外,内分泌学家和内科医生必须接受关于TBI所致垂体功能减退的教育,并鼓励他们积极与其他医生分享专业知识。